Wells Fargo Upgrades Relay Therapeutics to Overweight, Raises Price Target to $13

Benzinga · 1d ago
Wells Fargo analyst Eva Fortea Verdejo upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and raises the price target from $6 to $13.